A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
Clinical trial NCT04868760 · COMPLETED
Trial details
- NCT number
- NCT04868760
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-31
- Primary completion
- 2022-05-02
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.